0001140361-23-029929.txt : 20230614
0001140361-23-029929.hdr.sgml : 20230614
20230614211542
ACCESSION NUMBER: 0001140361-23-029929
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230614
FILED AS OF DATE: 20230614
DATE AS OF CHANGE: 20230614
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Garren Hideki
CENTRAL INDEX KEY: 0001854126
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35676
FILM NUMBER: 231015822
MAIL ADDRESS:
STREET 1: C/O PROTHENA BIOSCIENCES INC
STREET 2: 331 OYSTER POINT BOULEVARD
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PROTHENA CORP PUBLIC LTD CO
CENTRAL INDEX KEY: 0001559053
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: L2
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 77 SIR JOHN ROGERSON'S QUAY, BLOCK C
STREET 2: GRAND CANAL DOCKLANDS
CITY: DUBLIN 2
STATE: L2
ZIP: D02 VK60
BUSINESS PHONE: 011-353-1-236-2500
MAIL ADDRESS:
STREET 1: 77 SIR JOHN ROGERSON'S QUAY, BLOCK C
STREET 2: GRAND CANAL DOCKLANDS
CITY: DUBLIN 2
STATE: L2
ZIP: D02 VK60
FORMER COMPANY:
FORMER CONFORMED NAME: Prothena Corp plc
DATE OF NAME CHANGE: 20121102
FORMER COMPANY:
FORMER CONFORMED NAME: Neotope Corp Ltd
DATE OF NAME CHANGE: 20120926
4
1
form4.xml
X0407
4
2023-06-14
0001559053
PROTHENA CORP PUBLIC LTD CO
PRTA
0001854126
Garren Hideki
C/O PROTHENA BIOSCIENCES INC
331 OYSTER POINT BOULEVARD
SOUTH SAN FRANCISCO
CA
94080
true
Chief Medical Officer
true
Ordinary Shares, par value $0.01 per share
2023-06-14
4
M
0
4669
24.9
A
4669
D
Ordinary Shares, par value $0.01 per share
2023-06-14
4
S
0
509
72.4539
D
4160
D
Ordinary Shares, par value $0.01 per share
2023-06-14
4
S
0
971
73.3098
D
3189
D
Ordinary Shares, par value $0.01 per share
2023-06-14
4
S
0
2534
74.5895
D
655
D
Ordinary Shares, par value $0.01 per share
2023-06-14
4
S
0
655
75.4858
D
0
D
Stock Option (Right to Buy)
24.9
2023-06-14
4
M
0
4669
0
D
2031-04-05
Ordinary Shares
4669
205331
D
The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 16, 2023.
The transaction was executed in multiple trades in prices ranging from $71.96 to $72.91, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in footnotes 2 through 5 of this Form 4.
The transaction was executed in multiple trades in prices ranging from $73.03 to $73.995, inclusive.
The transaction was executed in multiple trades in prices ranging from $74.16 to $75.13, inclusive.
The transaction was executed in multiple trades in prices ranging from $75.26 to $76.20, inclusive.
The shares subject to the option vested and became exercisable as to 25% of the total number of shares subject to the option on April 5, 2022, and vest and become exercisable with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.
/s/ Michael Malecek, as attorney-in-fact for Hideki Garren
2023-06-14